Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Frequently asked questions
What sector does Eupraxia Pharmaceuticals Inc (EPRX) operate in?
Eupraxia Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Eupraxia Pharmaceuticals Inc (EPRX) current stock price?
As of the latest data, Eupraxia Pharmaceuticals Inc stock price is $6.96, with a previous close of $6.85. Eupraxia Pharmaceuticals Inc gained $0.11 in the last trading session, representing a 1.61% increase.
What is Eupraxia Pharmaceuticals Inc (EPRX) current market capitalization?
Eupraxia Pharmaceuticals Inc market cap is approximately 459.87 million.
What is Eupraxia Pharmaceuticals Inc (EPRX) Earnings Per Share (EPS)?
The trailing EPS is -$1.01, and the forward EPS is -$1.04.
What is Eupraxia Pharmaceuticals Inc (EPRX) EBITDA?
Eupraxia Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.33 million.
Does Eupraxia Pharmaceuticals Inc (EPRX) pay dividends?
No. Eupraxia Pharmaceuticals Inc does not pay a dividend.
When is Eupraxia Pharmaceuticals Inc (EPRX) next earnings report?
Eupraxia Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is Eupraxia Pharmaceuticals Inc (EPRX) beta (volatility) score?
Eupraxia Pharmaceuticals Inc has a beta of 1.487, suggesting it is more volatile than the market.
